{"ticker": {"uuid": "323933bd-d604-487a-b266-1b45c0fbdd45", "symbol": "WVE", "name": "Wave Life Sciences Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?", "summary": "Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating a positive shift in its earnings outlook. This upgrade is based on upward revisions in earnings estimates, which Zacks analysis suggests is a powerful predictor of near-term stock price movemen", "url": "https://sg.finance.yahoo.com/news/wave-life-sciences-wve-upgraded-160002968.html", "source_name": "Market source", "published_at": "2026-07-22T16:10:19", "published_display": "22 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Wave Life Sciences (WVE) Undervalued Or Is Its RNA Pipeline Already Priced In?", "summary": "Wave Life Sciences (WVE) has seen recent share price fluctuations, with a weak short-term trend but strong long-term returns. Investors are divided, with one narrative suggesting the stock is undervalued at $22.19 based on its RNA pipeline and upcoming clinical data, while anothe", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/is-wave-life-sciences-wve-undervalued-or-is-its-rna-pipeline", "source_name": "Simply Wall Street", "published_at": "2026-07-22T02:39:55", "published_display": "22 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Ltd. (WVE) Stock Analysis: Unveiling a Potential 282.85% Upside in Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNdURWUU5EdVlrczNOWVVobFNfQk9MTkJMTG9haC1sVTZhQ2ZURVRoWUtyWUx1bDR4NXRRNlNrUW1BUFNDQUVlcE5pdm9TbjhBVDFDV3RQNlRJR0tLODlELWdNLVNuOXRBSUtjNndGdWFmckNXT1pINjlwaXhDRU0zaUFLSjZWRk96dU5IaUdOckM4SEhic3YxRlI2QVBqNzU5TkxDeHE0N0NZRURVUVJFUm9tX1BMWFV5WGNRY01BRnNhYVQ5aFpHaGlmdEw5U3ljaGJ3V2pn?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-21T09:22:27+00:00", "published_display": "21 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WAVE LIFE SCIENCES LTD (WVE) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBJOF9CdE82bVc1QzdYWjdzTWk1bzQyaGliNlllSVdWZ21LaDNwajg5VmZKVE1Hb2dUemFKMkJEZGlDTExWMDl3eGFrLWpzeURkbUZqdU5VWl9mUHlRcTM1Wl9kYw?oc=5", "source_name": "ChartMill", "published_at": "2026-07-20T20:10:07+00:00", "published_display": "20 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Pte. Ltd (WVE) Q1 2025 Earnings Report - Results, Call & Slides", "summary": "Wave Life Sciences (WVE) released its Q1 2025 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$0.29 against a consensus of -$0.26 and actual revenue of $9.18 million compared to an expected $11.92 million. The revenue marked a si", "url": "https://www.tipranks.com/stocks/wve/earnings/q1-2025-report", "source_name": "TipRanks", "published_at": "2026-07-19T07:39:27", "published_display": "19 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ETFs Investing in Wave Life Sciences Ltd. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Wave Life Sciences Ltd. (1U5) stocks, providing financial details for each fund. The ETFs cover different investment styles and sectors, including small-cap, health care, and biotechnology, offering diverse investm", "url": "https://www.tradingview.com/symbols/SWB-1U5/etfs/", "source_name": "TradingView", "published_at": "2026-07-14T01:41:54", "published_display": "14 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "WVE Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "WAVE Life Sciences Ltd (WVE) exhibits a remarkable 100.00% gross margin, indicating strong pricing power and manufacturing efficiency. Despite this, the company faces challenges with negative operating and net margins, at -81.83% and -68.21% respectively, alongside a Return on Eq", "url": "https://intellectia.ai/en/stock/WVE/financials", "source_name": "Intellectia AI", "published_at": "2026-07-13T00:13:00", "published_display": "13 Jul 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Wave Life Sciences (WVE) Fallen Far Enough To Look Fairly Valued?", "summary": "Wave Life Sciences (WVE) stock has dropped significantly in 2026, yet still appears expensive when evaluated using traditional metrics, particularly its Price-to-Sales (P/S) ratio of 16.7x compared to an industry average of 6.7x. Despite recent progress in its RNA programs, the c", "url": "https://www.sahmcapital.com/news/content/has-wave-life-sciences-wve-fallen-far-enough-to-look-fairly-valued-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-11T00:10:07", "published_display": "11 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) 44th Annual J.P. Morgan Healthcare Conference Summary", "summary": "Wave Life Sciences (WVE) presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining its strategic vision to leverage RNA medicines with proprietary chemistry and deep genetic insights. The company is well-capitalized with a cash runway into Q3 2028 and is focusing ", "url": "https://quartr.com/events/wave-life-sciences-wve-44th-annual-j-p-morgan-healthcare-conference_FLslvv5a", "source_name": "Quartr", "published_at": "2026-07-09T00:40:14", "published_display": "09 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Jefferies London Healthcare Conference 2025 Summary", "summary": "Wave Life Sciences (WVE) presented a summary of their Jefferies London Healthcare Conference 2025, highlighting their focus on an integrated RNA medicines platform for genetic diseases. Key updates included the Inhibin E program (WVE-007) for obesity, showing promising preclinica", "url": "https://quartr.com/events/wave-life-sciences-ltd-wve-jefferies-london-healthcare-conference-2025_FLslJqoW", "source_name": "Quartr", "published_at": "2026-07-08T23:42:26", "published_display": "08 Jul 2026 23:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Wave Life Sciences Announces Singapore Court Hearing, to Be Held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation", "summary": "Wave Life Sciences has announced that the Singapore Court will hold a hearing on July 14, 2026, to approve its scheme of arrangement for redomiciliation. This move is part of the company's strategic efforts to change its domicile. The hearing is a crucial step in the redomiciliat", "url": "https://www.moomoo.com/th/news/post/72604376/press-release-wave-life-sciences-announces-singapore-court-hearing-to", "source_name": "Moomoo", "published_at": "2026-07-08T12:09:32", "published_display": "08 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation", "summary": "Wave Life Sciences has announced that the Singapore Court will hold a hearing on July 14, 2026, to approve its Scheme of Arrangement for redomiciliation to the United States. The company previously obtained shareholder approval for this move, which involves a statutory procedure ", "url": "https://finance.yahoo.com/healthcare/articles/wave-life-sciences-announces-singapore-201500963.html?.tsrc=rss", "source_name": "Market source", "published_at": "2026-07-07T22:50:56", "published_display": "07 Jul 2026 22:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences' Redomiciliation Scheme Set for Singapore Court Hearing", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/wave-life-sciences-apos-redomiciliation-213427944.html", "source_name": "MT Newswires", "published_at": "2026-07-07T21:34:27+00:00", "published_display": "07 Jul 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences court hearing set for July 14 on redomiciliation", "summary": "Wave Life Sciences has scheduled a court hearing in Singapore for July 14, 2026, to seek approval for its redomiciliation to the United States. The biotechnology company, which has seen stock volatility recently, holds more cash than debt and is attracting positive analyst rating", "url": "https://www.investing.com/news/company-news/wave-life-sciences-court-hearing-set-for-july-14-on-redomiciliation-93CH-4780061", "source_name": "Investing.com", "published_at": "2026-07-07T21:09:50", "published_display": "07 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life faces July 14 Singapore court hearing on U.S. redomicile", "summary": "Wave Life Sciences has obtained shareholder approval for its redomiciliation to the United States and is awaiting a Singapore High Court hearing on July 14, 2026, to approve the scheme of arrangement. The company has filed the necessary application, and the court has set deadline", "url": "https://www.stocktitan.net/news/WVE/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-s41s7v7c9bxy.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:41:58", "published_display": "07 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Announces Singapore Court Hearing, to be", "summary": "Wave Life Sciences (NASDAQ: WVE) announced that the Singapore High Court will hear its application to approve a scheme of arrangement for its proposed re-domiciliation to the United States on July 14, 2026. The company had previously obtained shareholder approval for this move. T", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323631/0/en/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-july-14-2026-to-approve-scheme-of-arrangement-for-redomiciliation.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T16:15:00", "published_display": "07 Jul 2026 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial", "summary": "Wave Life Sciences (WVE) saw its stock rise by 7.4% after moving its RNA-based obesity drug, WVE-007, into a Phase 2a trial. This advancement follows promising Phase 1 data showing reductions in waist circumference, visceral fat, and total fat. The drug, a GalNAc-siRNA monotherap", "url": "https://www.sahmcapital.com/news/content/wave-life-sciences-wve-is-up-74-after-advancing-rna-based-obesity-drug-into-phase-2a-trial-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-05T22:50:56", "published_display": "05 Jul 2026 22:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Wave Life Sciences (WVE) Undervalued On Its New Obesity Trial Progress?", "summary": "Wave Life Sciences (WVE) has initiated the Phase 2a multidose part of its INLIGHT trial for obesity drug candidate WVE-007, following positive Phase 1 data. Despite recent share price weakness, analysts consider the stock undervalued with a fair value of $22.19 against its curren", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/is-wave-life-sciences-wve-undervalued-on-its-new-obesity-tri", "source_name": "Simply Wall Street", "published_at": "2026-07-02T20:39:08", "published_display": "02 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?", "summary": "Wave Life Sciences (WVE) stock has gained 2.1% in the past four weeks, with Wall Street analysts projecting a potential upside of 294.7% based on a mean target price of $22.93. While price targets are cautioned as potentially misleading, a positive trend in earnings estimate revi", "url": "https://finance.yahoo.com/markets/stocks/articles/does-wave-life-sciences-wve-135502868.html", "source_name": "Market source", "published_at": "2026-07-01T14:10:37", "published_display": "01 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM Trial", "summary": "Wave Life Sciences (WVE) has initiated the multidose Phase 2a of its INLIGHT trial to evaluate WVE-007, an experimental GalNAc-siRNA, as a monotherapy for obesity with comorbidities. This follows promising results from the Phase 1 single-dose component, which showed clinically si", "url": "https://finance.yahoo.com/healthcare/articles/wave-life-sciences-wve-initiates-163450520.html", "source_name": "Market source", "published_at": "2026-06-30T16:34:00", "published_display": "30 Jun 2026 16:34", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "This article provides limited financial information for Wave Life Sciences Ltd. (NASDAQ: WVE), specifically mentioning its \"Price to earnings forward.\" The content is part of a TradingView page, indicating it's likely a data point rather than an in-depth analysis. Most of the pro", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T04:10:53", "published_display": "29 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "The article focuses on the enterprise value to EBIT forward for Wave Life Sciences Ltd. (NASDAQ: WVE). It is a financial data point presented within the TradingView platform, showing that for the reported period, the value is listed as \"No trades.\" The page provides financial ove", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:10:37", "published_display": "27 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Wave Life Sciences\u2019 (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning?", "summary": "Wave Life Sciences has advanced its investigational RNA therapy, WVE-007, into Phase 2a for obesity, with plans to combine it with incretins and use it as a post-incretin maintenance approach. This move, alongside the RestorAATion 2 data for WVE-006, is seen as crucial for the co", "url": "https://www.sahmcapital.com/news/content/does-wave-life-sciences-wve-rna-obesity-program-signal-a-shift-in-its-competitive-positioning-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-27T19:40:20", "published_display": "27 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "This page from TradingView displays the \"Price to sales forward\" for Wave Life Sciences Ltd. (NASDAQ: WVE). It indicates that the market is currently closed, and no trades have occurred for this specific metric. The content emphasizes that the data is provided by various financia", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:09:24", "published_display": "27 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "This article provides a financial metric for Wave Life Sciences Ltd. (NASDAQ: WVE), specifically its enterprise value to EBITDA forward. It indicates a period value and details regarding changes in this metric, noting that the content is provided by various financial data service", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:10:06", "published_display": "27 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "This article focuses on the enterprise value to revenue forward of Wave Life Sciences Ltd. (NASDAQ:WVE). It provides a brief mention of this financial metric within the context of the company's financial overview on TradingView. The article itself is very sparse and primarily con", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:35", "published_display": "27 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Ltd. Actuals & Estimates (NASDAQ:WVE)", "summary": "This article provides an overview of Wave Life Sciences Ltd. (NASDAQ:WVE) stock, including its current price, market capitalization, and historical performance. It also details actual and estimated financial data, analyst forecasts for future price targets, and upcoming earnings ", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T18:10:06", "published_display": "26 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) shareholders approve Singapore Scheme for redomiciliation", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOa1c1em9lU1FCMnV6RVp0RUhDcG1lMGduUi1RcTBIOHIxTHI5cnoxRnJMb3JBWk42V0lBTmJQTXB1UnRJbmxyaVI3ZXFNdnEyTVNjSllNakNSb01JQXNpUUIwajFWN2FXNmVDYVJNNXdlTlNpYWh2OG1yRFZDa1pUNlgtRnlhMGRqRVUzMkhrUFlWaTlxV1lmLS1CVVJiOWhUVWx5amxNMzl1TFVZMWNR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPQTVxWEZENE5jaDhtdHJlNE15b1JlVjJvdlNfRGxWYV9ZVlRWTnl3dWhmcTB1N0lXY0Vla2RndERBSEpzeHFpM0E2UTcwSnZPNnlFclZqSkpQLWhWcnhRbmZkRm5YUW95cmxUSjlmUHI4cU1VdnJQNmZZTzJ3T3VyQjBCUkxFVGZMWVkzcTE4MlpVTjRQY3c?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Faces Setback As WVE-007 Fails And Investor Exits", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences CEO to speak at two June investor conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNNmZlNXliZGk2WVVUWl8xVkF6TllWMDdjVlZSNE04bnBXODY2TVpLaUJUUVdHUVFoUXVuS1VvRC0tSEF6NXFVeUZ4YVN2elhtdVJHRXowZHJZa1drTDFKX3pWUk5UTFlTb2tCZjZJTXR4dlQ5M0NUS1dtd2Q4MGNlWGhUZ2I5OW9GWnpWd3N6RGpZbnRBM3E2Z21MM3VWampJV3Z4b050RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adage (NASDAQ: WVE) discloses 1,000,000-share stake, 0.53% of class", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNcEU3dWF2S0lZV0E1aGp2MDZmWVZXMUJqRFVUYU5HSVJ3NkpBSkpFeWR3T2V0eDFISmhZRXFZQTFKRTBpd1lxRHp1OGpqeEh4RUJXSXk1eWhuTmlsU2t6Zi0zWXZqeUhHWHBwR29ReUJrMENLV1Exc3k0UVp4eXI4YVZhRGZ1akxDSWZONVMxZHdoU29ia0hoTmNRcFAzTHNkTUdxSW9CUjZ1RmhsUmtmNFd5Um1JcmhXWWUtTXV3SWxyeTkxNm1NQ3Zn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Growth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOdUdMRXlmMWE0QnJxTUdqQkRwUGZDTzBRUTJEaGpmMDZMQjlhT0tpZFBOOEVMWVRvZVBPeGhvYTFVa1pnLXAwRmw3eF84QUl1Wld6aE1VYkQzVHMtUzk2V1ZibndPdURkSzFLSlhiRFdBWkFQSUxwdlZqcFlUSHBNM1U4cjM2YVZlNjFKYUtnZXFzRmZZQWJKT1NDcTVTb1dubm5xTmpRVQ?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC takes 2.8% position in Wave Life Sciences (NASDAQ: WVE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPQUVhVURndVl6R3k1d3RqanpXbC1fZE01UllsbzBaMTVtai1hRnRwNy16ZXM0UU92MHJRX0hHUjFhOFNDYUNPYkc2M3VBeFpqM0k5dFl5VU96WlJ1c3NjRmFyR1pjanpORjl6YWVIN25idnp6cmViR1Nzc0hUdl9pN2JiQU1XeG9Ka3NwajJ0TXhLVTU2dFEwR1pqUVVDaHVVemV5RnJ0NGdCMHpOZmVvd1F6RkhWVm83RVY2UXpTalF3eUZKWjFvVU5R?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Q1 Revenue Surge Tests Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WAVE LIFE SCIENCES ($WVE) Releases Q1 2026 Earnings | WVE Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNLVZMc2JqRFgzdi1lbGxFQzMtQU5KZEY3NlhKZDZReXNuend6clFJa1c3TXo1dTc5MkJhWVhqZW8xLVhUdnBmOW1Iejg0SGlRTktNQWhuWDRFb184MEpQY253TDZ1cmFnemxDS2xKTEZVZ0ZmVGQyN1ExUUs5TFZVRzFMVUs5U3NteHptWHVoaGplazA0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQVkUzcS1BcjdXeVc0Z2loYUpoSElfOE9Nby1IV3lHSEt3dXB6UnhWQ21zVl9TVEtnUGZxaHJ0U1draW9YR3FyemIyWWltaG1QSUF5MV9Wa2xhQjgzT204ZnV1VkRQNFAtWVV1OFpBajB2VU9vWTZEejlQY3JiNlBsdUxONzVtc25ydUFleTZhV1NoUVB1T05uOU9pOA?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright Highlight Misread Risk in Wave Life Sciences Ltd. (WVE) Clinical Data Reaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPNnNXdHFfNW1mNXZRMmhnTlNyNy02UDdTaDhleHBBbGUxYUIyRXcycnh3UHJYcHl0ZnZHM1FwNHktSzRNejVUWTd2NnNXcnNQb3NVcW44U3JidjNpbHFzVjlJZ1Rhd1ZNVGdSXzBqZzhCWjRlVWhDYXhKeG5kWHFOek83MFM5S3QtOWMweEdVQkoyb2l3blUwWm90ODljOUcxUndR?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Wave Life Sciences (WVE) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPLWU5ZXExa3VXMU9SY2M1ejdCcHRuaXF1Ym9jSDNySGZXZHdEM084aWRCOTJ1UFJjZ3NFM29aa1JTY2M4by1paTFnb1VHQ184ZzhyUlhZaWZ5eUhScHY4SnY5Ry1PbTR0VWZsRFF0eW9zYkN6UUlXdEVuQU03OVdMY3pDSllQZGhERkFtVlo2YUlHczZHZlFR?oc=5", "source_name": "Market source", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Proposes Redomiciliation to the United States to Enhance Shareholder Value and Streamline Operations 1 \u2013 Minichart", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQLUVKekRkMlN4dkVOWEpVdkRzbF9DT04xblZ1czJpNWlldnlpY2hkdnJLUnlOSVNpY3pwVXlxLW8xUDVDYktKNUtDYTUzYkRiVk1JS1A3N0JLa0ZEX0JZYzgwNHlZaEQyVUUzQVh3X0FwLXM0bDVMNklReDZaelVUMERNVDBGeDk5bmdyNVl1ZVlvVHBwSGNmeG52bVZBSTlocXh3UlgwcjU3RDBCM3p0VFRRTmVUOFBaT2JCaVdSWmtYMzJ1ZnhhNVE2QXpCaEVidVV6VEx5RTQzU0N2NS0tYWdaUllSYmRoR2o3dVBiM2VhanZS?oc=5", "source_name": "Minichart", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQZUlRVi1LT0pYOG9kWjZCZjRlWXFSTTN3UkxtYjNUZzZtWnI0N3VtYnNLeVMwZld5NzlZblVRN2Utd0NjQnNSMXNaR294YTRwNm1ZRGpSa2h6aV95d3poVXpQY1dkNzR4WElYRksxbm5YbEI1djVrOWFRZFU4aGdXNEx2a3l3dm1sZnpiZnBzTjVVbDZrdWkwZ0NB?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving RA Capital's Massive Bet on Wave Life Sciences", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZXBmZEI3ZTZVUWhub21wWExMclBRX1BDRl96MWxQU2lFNklkdGV5RHc1UVhTM3ZKMXphSUxZWDRDZG5PNGlPaEdRaGthejItMzBEMTNzYmFzTHB6V0tIYUlkOGp0OTg3aVpsbllmQUJ5SnpnUnJ0ZGJ1SmNJaDdMOElRWGxNOFdwMVhyN1NoTG5zdFNGRUpYaDN5d0w?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-31T02:08:31+00:00", "published_display": "31 Mar 2026 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPRGtGazBRRTdXVDNSVDdoVFFROE9CbVFmTWdNZ0V6aFhpdXdMZ1hkREc4cmtIV1pGa1JFcHV1TmJ3WGdKMnlnRWtYTVltUTQ1MmdXNjZTM3hlVXgtLUxjdDQ2UHZTZGJ6SUdyNDlQeHFJcFV3OUU5X0lpVU5iZE03VWpDZVk1dmJUazRPdGhjTTNYSFl0cF9LUTNPTHA?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences stock price crash is a buying opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPTXpLc3pEbVRqaXF3eUhuT3BmRGNpUnNZN2FuUHEyRTZQVzU0eUh0RkJYdGJpMDJUY0RLSWY0ZUFDcHpNcVRPMXdaNGpxY1pvYzlqMVg4cWRyUk9tTkJBUkhUZk5MMlhtc0toTE0zYWxZSU1zSTRYUVZGTVhrOG9URlZwTi1qcjhHaERIYzNMQ1VydW5oTWRNdFExVnd0Ukh5ZTlUdE45YzRnYzBoQXdsLWdxV21WZw?oc=5", "source_name": "Invezz", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences stock crash: why analyst sees a buying opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxObXpsOWpEZ3FFV3RGYXcwbks1SHZiRThick84a0J2QzA5YnRZZ0w1TGFHN3BtZ2FaZU45a3pfbEViZXlkT1BZSGQwS3EtLVhyYTZ1TUxYcFhUeUNxaHF0cWVXcF9BUDV6aXpKQUp2WVVvd0xEamFNYWE4QzlFczIzM1JaSGFtYTZSVFFQc1FZdHQ0UWJDdEIyVDNIWUlGV3NyamxUWFU5VEx5NVAxTl9MUmhuZmhHVnlseG5fY0c3ZGhXQUE?oc=5", "source_name": "TradingView", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Wave Life Sciences shares plunge 58% as data for high dose of obesity drug disappoints", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What Boosted Wave Life Sciences Ltd. (WVE) in Q4", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQaTJjbjFpQnJxZmYtR2FXSUdnc29INWsxZDVPYzJiYlpfc3NyVENWSklhODAyUmJkSEJSUzA5ZWhzdHotb3Q4R3YzNWJVa3hCbTcxZkVqNjIwekVJWnBZdS1Ma1R3TnZKdHptXzVYcDByX0RwdmtWdWNhQUJWLTRlR3V1dzg1MlVwUFJacHE0RFU4UVBFaU03VnExdw?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPZHd6YlBWRVZZRHpEWWFiVUIzWE50UlJPZlpIVGVXTGFHTXd0MnQ5Mzdac3lISnUzcUYxRXRXeWtEbm83UXpKMFRxLTFqOFRvUThCR0UzekdsbUNYZHFRLVdYcG5MY19YWU1pY1pUZWh1M2dpNDlTUVdVdFZxaVhKWVpNMGJVQQ?oc=5", "source_name": "Market source", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYVJ2M0dBeG9VYWxZM1l0ejNPSTU0b0lJQ2pESVpYNFFERlRBa2dleWdPMVFvYU5yME1rMjlVcWpId1V2YTVEQU1KZEd0eGoyVjlIcnNpQzgwZWRsc1dSOHRUNUpCem1WYlk3N0h1eURNVl9KeU9sMFkxUEw1SnhlSm83YU1FM29PLThF?oc=5", "source_name": "Market source", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?", "summary": "Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating a positive shift in its earnings outlook. This upgrade is based on upward revisions in earnings estimates, which Zacks analysis suggests is a powerful predictor of near-term stock price movemen", "url": "https://sg.finance.yahoo.com/news/wave-life-sciences-wve-upgraded-160002968.html", "source_name": "Market source", "published_at": "2026-07-22T16:10:19", "published_display": "22 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Wave Life Sciences (WVE) Undervalued Or Is Its RNA Pipeline Already Priced In?", "summary": "Wave Life Sciences (WVE) has seen recent share price fluctuations, with a weak short-term trend but strong long-term returns. Investors are divided, with one narrative suggesting the stock is undervalued at $22.19 based on its RNA pipeline and upcoming clinical data, while anothe", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/is-wave-life-sciences-wve-undervalued-or-is-its-rna-pipeline", "source_name": "Simply Wall Street", "published_at": "2026-07-22T02:39:55", "published_display": "22 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Ltd. (WVE) Stock Analysis: Unveiling a Potential 282.85% Upside in Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxNdURWUU5EdVlrczNOWVVobFNfQk9MTkJMTG9haC1sVTZhQ2ZURVRoWUtyWUx1bDR4NXRRNlNrUW1BUFNDQUVlcE5pdm9TbjhBVDFDV3RQNlRJR0tLODlELWdNLVNuOXRBSUtjNndGdWFmckNXT1pINjlwaXhDRU0zaUFLSjZWRk96dU5IaUdOckM4SEhic3YxRlI2QVBqNzU5TkxDeHE0N0NZRURVUVJFUm9tX1BMWFV5WGNRY01BRnNhYVQ5aFpHaGlmdEw5U3ljaGJ3V2pn?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-21T09:22:27+00:00", "published_display": "21 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WAVE LIFE SCIENCES LTD (WVE) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBJOF9CdE82bVc1QzdYWjdzTWk1bzQyaGliNlllSVdWZ21LaDNwajg5VmZKVE1Hb2dUemFKMkJEZGlDTExWMDl3eGFrLWpzeURkbUZqdU5VWl9mUHlRcTM1Wl9kYw?oc=5", "source_name": "ChartMill", "published_at": "2026-07-20T20:10:07+00:00", "published_display": "20 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Pte. Ltd (WVE) Q1 2025 Earnings Report - Results, Call & Slides", "summary": "Wave Life Sciences (WVE) released its Q1 2025 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$0.29 against a consensus of -$0.26 and actual revenue of $9.18 million compared to an expected $11.92 million. The revenue marked a si", "url": "https://www.tipranks.com/stocks/wve/earnings/q1-2025-report", "source_name": "TipRanks", "published_at": "2026-07-19T07:39:27", "published_display": "19 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Wave Life Sciences Ltd. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Wave Life Sciences Ltd. (1U5) stocks, providing financial details for each fund. The ETFs cover different investment styles and sectors, including small-cap, health care, and biotechnology, offering diverse investm", "url": "https://www.tradingview.com/symbols/SWB-1U5/etfs/", "source_name": "TradingView", "published_at": "2026-07-14T01:41:54", "published_display": "14 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WVE Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "WAVE Life Sciences Ltd (WVE) exhibits a remarkable 100.00% gross margin, indicating strong pricing power and manufacturing efficiency. Despite this, the company faces challenges with negative operating and net margins, at -81.83% and -68.21% respectively, alongside a Return on Eq", "url": "https://intellectia.ai/en/stock/WVE/financials", "source_name": "Intellectia AI", "published_at": "2026-07-13T00:13:00", "published_display": "13 Jul 2026 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Wave Life Sciences (WVE) Fallen Far Enough To Look Fairly Valued?", "summary": "Wave Life Sciences (WVE) stock has dropped significantly in 2026, yet still appears expensive when evaluated using traditional metrics, particularly its Price-to-Sales (P/S) ratio of 16.7x compared to an industry average of 6.7x. Despite recent progress in its RNA programs, the c", "url": "https://www.sahmcapital.com/news/content/has-wave-life-sciences-wve-fallen-far-enough-to-look-fairly-valued-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-11T00:10:07", "published_display": "11 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) 44th Annual J.P. Morgan Healthcare Conference Summary", "summary": "Wave Life Sciences (WVE) presented at the 44th Annual J.P. Morgan Healthcare Conference, outlining its strategic vision to leverage RNA medicines with proprietary chemistry and deep genetic insights. The company is well-capitalized with a cash runway into Q3 2028 and is focusing ", "url": "https://quartr.com/events/wave-life-sciences-wve-44th-annual-j-p-morgan-healthcare-conference_FLslvv5a", "source_name": "Quartr", "published_at": "2026-07-09T00:40:14", "published_display": "09 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Jefferies London Healthcare Conference 2025 Summary", "summary": "Wave Life Sciences (WVE) presented a summary of their Jefferies London Healthcare Conference 2025, highlighting their focus on an integrated RNA medicines platform for genetic diseases. Key updates included the Inhibin E program (WVE-007) for obesity, showing promising preclinica", "url": "https://quartr.com/events/wave-life-sciences-ltd-wve-jefferies-london-healthcare-conference-2025_FLslJqoW", "source_name": "Quartr", "published_at": "2026-07-08T23:42:26", "published_display": "08 Jul 2026 23:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Wave Life Sciences Announces Singapore Court Hearing, to Be Held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation", "summary": "Wave Life Sciences has announced that the Singapore Court will hold a hearing on July 14, 2026, to approve its scheme of arrangement for redomiciliation. This move is part of the company's strategic efforts to change its domicile. The hearing is a crucial step in the redomiciliat", "url": "https://www.moomoo.com/th/news/post/72604376/press-release-wave-life-sciences-announces-singapore-court-hearing-to", "source_name": "Moomoo", "published_at": "2026-07-08T12:09:32", "published_display": "08 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation", "summary": "Wave Life Sciences has announced that the Singapore Court will hold a hearing on July 14, 2026, to approve its Scheme of Arrangement for redomiciliation to the United States. The company previously obtained shareholder approval for this move, which involves a statutory procedure ", "url": "https://finance.yahoo.com/healthcare/articles/wave-life-sciences-announces-singapore-201500963.html?.tsrc=rss", "source_name": "Market source", "published_at": "2026-07-07T22:50:56", "published_display": "07 Jul 2026 22:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences' Redomiciliation Scheme Set for Singapore Court Hearing", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/wave-life-sciences-apos-redomiciliation-213427944.html", "source_name": "MT Newswires", "published_at": "2026-07-07T21:34:27+00:00", "published_display": "07 Jul 2026 21:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences court hearing set for July 14 on redomiciliation", "summary": "Wave Life Sciences has scheduled a court hearing in Singapore for July 14, 2026, to seek approval for its redomiciliation to the United States. The biotechnology company, which has seen stock volatility recently, holds more cash than debt and is attracting positive analyst rating", "url": "https://www.investing.com/news/company-news/wave-life-sciences-court-hearing-set-for-july-14-on-redomiciliation-93CH-4780061", "source_name": "Investing.com", "published_at": "2026-07-07T21:09:50", "published_display": "07 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life faces July 14 Singapore court hearing on U.S. redomicile", "summary": "Wave Life Sciences has obtained shareholder approval for its redomiciliation to the United States and is awaiting a Singapore High Court hearing on July 14, 2026, to approve the scheme of arrangement. The company has filed the necessary application, and the court has set deadline", "url": "https://www.stocktitan.net/news/WVE/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-s41s7v7c9bxy.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:41:58", "published_display": "07 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Announces Singapore Court Hearing, to be", "summary": "Wave Life Sciences (NASDAQ: WVE) announced that the Singapore High Court will hear its application to approve a scheme of arrangement for its proposed re-domiciliation to the United States on July 14, 2026. The company had previously obtained shareholder approval for this move. T", "url": "https://www.globenewswire.com/news-release/2026/07/07/3323631/0/en/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-july-14-2026-to-approve-scheme-of-arrangement-for-redomiciliation.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T16:15:00", "published_display": "07 Jul 2026 16:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Is Up 7.4% After Advancing RNA-Based Obesity Drug Into Phase 2a Trial", "summary": "Wave Life Sciences (WVE) saw its stock rise by 7.4% after moving its RNA-based obesity drug, WVE-007, into a Phase 2a trial. This advancement follows promising Phase 1 data showing reductions in waist circumference, visceral fat, and total fat. The drug, a GalNAc-siRNA monotherap", "url": "https://www.sahmcapital.com/news/content/wave-life-sciences-wve-is-up-74-after-advancing-rna-based-obesity-drug-into-phase-2a-trial-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-05T22:50:56", "published_display": "05 Jul 2026 22:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Wave Life Sciences (WVE) Undervalued On Its New Obesity Trial Progress?", "summary": "Wave Life Sciences (WVE) has initiated the Phase 2a multidose part of its INLIGHT trial for obesity drug candidate WVE-007, following positive Phase 1 data. Despite recent share price weakness, analysts consider the stock undervalued with a fair value of $22.19 against its curren", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/is-wave-life-sciences-wve-undervalued-on-its-new-obesity-tri", "source_name": "Simply Wall Street", "published_at": "2026-07-02T20:39:08", "published_display": "02 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?", "summary": "Wave Life Sciences (WVE) stock has gained 2.1% in the past four weeks, with Wall Street analysts projecting a potential upside of 294.7% based on a mean target price of $22.93. While price targets are cautioned as potentially misleading, a positive trend in earnings estimate revi", "url": "https://finance.yahoo.com/markets/stocks/articles/does-wave-life-sciences-wve-135502868.html", "source_name": "Market source", "published_at": "2026-07-01T14:10:37", "published_display": "01 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM Trial", "summary": "Wave Life Sciences (WVE) has initiated the multidose Phase 2a of its INLIGHT trial to evaluate WVE-007, an experimental GalNAc-siRNA, as a monotherapy for obesity with comorbidities. This follows promising results from the Phase 1 single-dose component, which showed clinically si", "url": "https://finance.yahoo.com/healthcare/articles/wave-life-sciences-wve-initiates-163450520.html", "source_name": "Market source", "published_at": "2026-06-30T16:34:00", "published_display": "30 Jun 2026 16:34", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "This article provides limited financial information for Wave Life Sciences Ltd. (NASDAQ: WVE), specifically mentioning its \"Price to earnings forward.\" The content is part of a TradingView page, indicating it's likely a data point rather than an in-depth analysis. Most of the pro", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T04:10:53", "published_display": "29 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "The article focuses on the enterprise value to EBIT forward for Wave Life Sciences Ltd. (NASDAQ: WVE). It is a financial data point presented within the TradingView platform, showing that for the reported period, the value is listed as \"No trades.\" The page provides financial ove", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:10:37", "published_display": "27 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Wave Life Sciences\u2019 (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning?", "summary": "Wave Life Sciences has advanced its investigational RNA therapy, WVE-007, into Phase 2a for obesity, with plans to combine it with incretins and use it as a post-incretin maintenance approach. This move, alongside the RestorAATion 2 data for WVE-006, is seen as crucial for the co", "url": "https://www.sahmcapital.com/news/content/does-wave-life-sciences-wve-rna-obesity-program-signal-a-shift-in-its-competitive-positioning-2026-06-27", "source_name": "Sahm", "published_at": "2026-06-27T19:40:20", "published_display": "27 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "This page from TradingView displays the \"Price to sales forward\" for Wave Life Sciences Ltd. (NASDAQ: WVE). It indicates that the market is currently closed, and no trades have occurred for this specific metric. The content emphasizes that the data is provided by various financia", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:09:24", "published_display": "27 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "This article provides a financial metric for Wave Life Sciences Ltd. (NASDAQ: WVE), specifically its enterprise value to EBITDA forward. It indicates a period value and details regarding changes in this metric, noting that the content is provided by various financial data service", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T15:10:06", "published_display": "27 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Wave Life Sciences Ltd. \u2013 NASDAQ:WVE", "summary": "This article focuses on the enterprise value to revenue forward of Wave Life Sciences Ltd. (NASDAQ:WVE). It provides a brief mention of this financial metric within the context of the company's financial overview on TradingView. The article itself is very sparse and primarily con", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:35", "published_display": "27 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Ltd. Actuals & Estimates (NASDAQ:WVE)", "summary": "This article provides an overview of Wave Life Sciences Ltd. (NASDAQ:WVE) stock, including its current price, market capitalization, and historical performance. It also details actual and estimated financial data, analyst forecasts for future price targets, and upcoming earnings ", "url": "https://www.tradingview.com/symbols/NASDAQ-WVE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T18:10:06", "published_display": "26 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) shareholders approve Singapore Scheme for redomiciliation", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOa1c1em9lU1FCMnV6RVp0RUhDcG1lMGduUi1RcTBIOHIxTHI5cnoxRnJMb3JBWk42V0lBTmJQTXB1UnRJbmxyaVI3ZXFNdnEyTVNjSllNakNSb01JQXNpUUIwajFWN2FXNmVDYVJNNXdlTlNpYWh2OG1yRFZDa1pUNlgtRnlhMGRqRVUzMkhrUFlWaTlxV1lmLS1CVVJiOWhUVWx5amxNMzl1TFVZMWNR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPQTVxWEZENE5jaDhtdHJlNE15b1JlVjJvdlNfRGxWYV9ZVlRWTnl3dWhmcTB1N0lXY0Vla2RndERBSEpzeHFpM0E2UTcwSnZPNnlFclZqSkpQLWhWcnhRbmZkRm5YUW95cmxUSjlmUHI4cU1VdnJQNmZZTzJ3T3VyQjBCUkxFVGZMWVkzcTE4MlpVTjRQY3c?oc=5", "source_name": "Market source", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Faces Setback As WVE-007 Fails And Investor Exits", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences CEO to speak at two June investor conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNNmZlNXliZGk2WVVUWl8xVkF6TllWMDdjVlZSNE04bnBXODY2TVpLaUJUUVdHUVFoUXVuS1VvRC0tSEF6NXFVeUZ4YVN2elhtdVJHRXowZHJZa1drTDFKX3pWUk5UTFlTb2tCZjZJTXR4dlQ5M0NUS1dtd2Q4MGNlWGhUZ2I5OW9GWnpWd3N6RGpZbnRBM3E2Z21MM3VWampJV3Z4b050RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adage (NASDAQ: WVE) discloses 1,000,000-share stake, 0.53% of class", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNcEU3dWF2S0lZV0E1aGp2MDZmWVZXMUJqRFVUYU5HSVJ3NkpBSkpFeWR3T2V0eDFISmhZRXFZQTFKRTBpd1lxRHp1OGpqeEh4RUJXSXk1eWhuTmlsU2t6Zi0zWXZqeUhHWHBwR29ReUJrMENLV1Exc3k0UVp4eXI4YVZhRGZ1akxDSWZONVMxZHdoU29ia0hoTmNRcFAzTHNkTUdxSW9CUjZ1RmhsUmtmNFd5Um1JcmhXWWUtTXV3SWxyeTkxNm1NQ3Zn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Growth Investors: Industry Analysts Just Upgraded Their Wave Life Sciences Ltd. (NASDAQ:WVE) Revenue Forecasts By 91%", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOdUdMRXlmMWE0QnJxTUdqQkRwUGZDTzBRUTJEaGpmMDZMQjlhT0tpZFBOOEVMWVRvZVBPeGhvYTFVa1pnLXAwRmw3eF84QUl1Wld6aE1VYkQzVHMtUzk2V1ZibndPdURkSzFLSlhiRFdBWkFQSUxwdlZqcFlUSHBNM1U4cjM2YVZlNjFKYUtnZXFzRmZZQWJKT1NDcTVTb1dubm5xTmpRVQ?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC takes 2.8% position in Wave Life Sciences (NASDAQ: WVE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPQUVhVURndVl6R3k1d3RqanpXbC1fZE01UllsbzBaMTVtai1hRnRwNy16ZXM0UU92MHJRX0hHUjFhOFNDYUNPYkc2M3VBeFpqM0k5dFl5VU96WlJ1c3NjRmFyR1pjanpORjl6YWVIN25idnp6cmViR1Nzc0hUdl9pN2JiQU1XeG9Ka3NwajJ0TXhLVTU2dFEwR1pqUVVDaHVVemV5RnJ0NGdCMHpOZmVvd1F6RkhWVm83RVY2UXpTalF3eUZKWjFvVU5R?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Q1 Revenue Surge Tests Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "WAVE LIFE SCIENCES ($WVE) Releases Q1 2026 Earnings | WVE Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNLVZMc2JqRFgzdi1lbGxFQzMtQU5KZEY3NlhKZDZReXNuend6clFJa1c3TXo1dTc5MkJhWVhqZW8xLVhUdnBmOW1Iejg0SGlRTktNQWhuWDRFb184MEpQY253TDZ1cmFnemxDS2xKTEZVZ0ZmVGQyN1ExUUs5TFZVRzFMVUs5U3NteHptWHVoaGplazA0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQVkUzcS1BcjdXeVc0Z2loYUpoSElfOE9Nby1IV3lHSEt3dXB6UnhWQ21zVl9TVEtnUGZxaHJ0U1draW9YR3FyemIyWWltaG1QSUF5MV9Wa2xhQjgzT204ZnV1VkRQNFAtWVV1OFpBajB2VU9vWTZEejlQY3JiNlBsdUxONzVtc25ydUFleTZhV1NoUVB1T05uOU9pOA?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Highlight Misread Risk in Wave Life Sciences Ltd. (WVE) Clinical Data Reaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPNnNXdHFfNW1mNXZRMmhnTlNyNy02UDdTaDhleHBBbGUxYUIyRXcycnh3UHJYcHl0ZnZHM1FwNHktSzRNejVUWTd2NnNXcnNQb3NVcW44U3JidjNpbHFzVjlJZ1Rhd1ZNVGdSXzBqZzhCWjRlVWhDYXhKeG5kWHFOek83MFM5S3QtOWMweEdVQkoyb2l3blUwWm90ODljOUcxUndR?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Wave Life Sciences (WVE) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPLWU5ZXExa3VXMU9SY2M1ejdCcHRuaXF1Ym9jSDNySGZXZHdEM084aWRCOTJ1UFJjZ3NFM29aa1JTY2M4by1paTFnb1VHQ184ZzhyUlhZaWZ5eUhScHY4SnY5Ry1PbTR0VWZsRFF0eW9zYkN6UUlXdEVuQU03OVdMY3pDSllQZGhERkFtVlo2YUlHczZHZlFR?oc=5", "source_name": "Market source", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Proposes Redomiciliation to the United States to Enhance Shareholder Value and Streamline Operations 1 \u2013 Minichart", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQLUVKekRkMlN4dkVOWEpVdkRzbF9DT04xblZ1czJpNWlldnlpY2hkdnJLUnlOSVNpY3pwVXlxLW8xUDVDYktKNUtDYTUzYkRiVk1JS1A3N0JLa0ZEX0JZYzgwNHlZaEQyVUUzQVh3X0FwLXM0bDVMNklReDZaelVUMERNVDBGeDk5bmdyNVl1ZVlvVHBwSGNmeG52bVZBSTlocXh3UlgwcjU3RDBCM3p0VFRRTmVUOFBaT2JCaVdSWmtYMzJ1ZnhhNVE2QXpCaEVidVV6VEx5RTQzU0N2NS0tYWdaUllSYmRoR2o3dVBiM2VhanZS?oc=5", "source_name": "Minichart", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQZUlRVi1LT0pYOG9kWjZCZjRlWXFSTTN3UkxtYjNUZzZtWnI0N3VtYnNLeVMwZld5NzlZblVRN2Utd0NjQnNSMXNaR294YTRwNm1ZRGpSa2h6aV95d3poVXpQY1dkNzR4WElYRksxbm5YbEI1djVrOWFRZFU4aGdXNEx2a3l3dm1sZnpiZnBzTjVVbDZrdWkwZ0NB?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving RA Capital's Massive Bet on Wave Life Sciences", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPZXBmZEI3ZTZVUWhub21wWExMclBRX1BDRl96MWxQU2lFNklkdGV5RHc1UVhTM3ZKMXphSUxZWDRDZG5PNGlPaEdRaGthejItMzBEMTNzYmFzTHB6V0tIYUlkOGp0OTg3aVpsbllmQUJ5SnpnUnJ0ZGJ1SmNJaDdMOElRWGxNOFdwMVhyN1NoTG5zdFNGRUpYaDN5d0w?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-31T02:08:31+00:00", "published_display": "31 Mar 2026 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPRGtGazBRRTdXVDNSVDdoVFFROE9CbVFmTWdNZ0V6aFhpdXdMZ1hkREc4cmtIV1pGa1JFcHV1TmJ3WGdKMnlnRWtYTVltUTQ1MmdXNjZTM3hlVXgtLUxjdDQ2UHZTZGJ6SUdyNDlQeHFJcFV3OUU5X0lpVU5iZE03VWpDZVk1dmJUazRPdGhjTTNYSFl0cF9LUTNPTHA?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences stock price crash is a buying opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPTXpLc3pEbVRqaXF3eUhuT3BmRGNpUnNZN2FuUHEyRTZQVzU0eUh0RkJYdGJpMDJUY0RLSWY0ZUFDcHpNcVRPMXdaNGpxY1pvYzlqMVg4cWRyUk9tTkJBUkhUZk5MMlhtc0toTE0zYWxZSU1zSTRYUVZGTVhrOG9URlZwTi1qcjhHaERIYzNMQ1VydW5oTWRNdFExVnd0Ukh5ZTlUdE45YzRnYzBoQXdsLWdxV21WZw?oc=5", "source_name": "Invezz", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences stock crash: why analyst sees a buying opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxObXpsOWpEZ3FFV3RGYXcwbks1SHZiRThick84a0J2QzA5YnRZZ0w1TGFHN3BtZ2FaZU45a3pfbEViZXlkT1BZSGQwS3EtLVhyYTZ1TUxYcFhUeUNxaHF0cWVXcF9BUDV6aXpKQUp2WVVvd0xEamFNYWE4QzlFczIzM1JaSGFtYTZSVFFQc1FZdHQ0UWJDdEIyVDNIWUlGV3NyamxUWFU5VEx5NVAxTl9MUmhuZmhHVnlseG5fY0c3ZGhXQUE?oc=5", "source_name": "TradingView", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US Stocks: Wave Life Sciences shares plunge 58% as data for high dose of obesity drug disappoints", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s What Boosted Wave Life Sciences Ltd. (WVE) in Q4", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQaTJjbjFpQnJxZmYtR2FXSUdnc29INWsxZDVPYzJiYlpfc3NyVENWSklhODAyUmJkSEJSUzA5ZWhzdHotb3Q4R3YzNWJVa3hCbTcxZkVqNjIwekVJWnBZdS1Ma1R3TnZKdHptXzVYcDByX0RwdmtWdWNhQUJWLTRlR3V1dzg1MlVwUFJacHE0RFU4UVBFaU03VnExdw?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPZHd6YlBWRVZZRHpEWWFiVUIzWE50UlJPZlpIVGVXTGFHTXd0MnQ5Mzdac3lISnUzcUYxRXRXeWtEbm83UXpKMFRxLTFqOFRvUThCR0UzekdsbUNYZHFRLVdYcG5MY19YWU1pY1pUZWh1M2dpNDlTUVdVdFZxaVhKWVpNMGJVQQ?oc=5", "source_name": "Market source", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYVJ2M0dBeG9VYWxZM1l0ejNPSTU0b0lJQ2pESVpYNFFERlRBa2dleWdPMVFvYU5yME1rMjlVcWpId1V2YTVEQU1KZEd0eGoyVjlIcnNpQzgwZWRsc1dSOHRUNUpCem1WYlk3N0h1eURNVl9KeU9sMFkxUEw1SnhlSm83YU1FM29PLThF?oc=5", "source_name": "Market source", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 58, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 39, "score": 54, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.76, "count": 20}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 5.82, "latest_week": "2026-07-17", "one_week_move": -6.9, "four_week_move": -5.5, "twelve_week_move": -18.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.288482, "market_dynamics_buy_signal": false, "relative_strength": -44.34499, "fair_value_gap": -26.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 53.8462, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.9% over one week, -5.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 20}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Sahm", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "Quartr", "count": 2}, {"label": "DirectorsTalk Interviews", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 20}, {"label": "Regulatory and legal", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.9% over one week, -5.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Wave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?"}], "updated_at": "2026-07-23T10:28:40.991470+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}